Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

Former Shire CEO Flemming Ørnskov will lead newly independent Galderma Laboratories L.P. as CEO. Joining him is fellow Shire vet Thomas Dittrich, who will be CFO, the same post he held at Shire. The pair led Shire through its $62 billion acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) (see “Takeda Hits the Gas”).

Ørnskov succeeds Stuart Raetzman, who joins the dermatology company’s board. The former Nestlé Skin Health unit became an independent company last week as part of a $10 billion spinout from Nestlé S.A. (SWX:NESN)...